allafrica.com
New Treatments for Non-Communicable Diseases Launched in Uganda
C&D Pharma launches three innovative treatments for non-communicable diseases in Uganda with support from the Ministry of Health and other partners.
English
Nigeria
HealthPublic HealthHealthcarePharmaceuticalsUgandaDisease Treatment
C&D PharmaMinistry Of Health (Uganda)Joint Medical Stores (Jms)Kamcare
Dr. Charles OlaroChirag VoraDr Emmanuel Higenyi
- What new treatments did C&D Pharma launch in Uganda?
- C&D Pharma launched three new treatments for non-communicable diseases in Uganda: Cliniplan Trio for hypertension, Dairetin Family for diabetes, and Daptide for diabetes and hypertension.
- Which organizations supported the launch of these new treatments?
- The Ugandan Ministry of Health, Joint Medical Stores (JMS), and KAMCARE supported the launch, aiming to improve access to affordable treatments for hypertension, diabetes, kidney disease, and cardiovascular diseases.
- What is C&D Pharma's commitment to improving healthcare in Uganda?
- C&D Pharma aims to improve health and well-being in Uganda through partnerships with the Ministry of Health, JMS, and KAMCARE, ensuring wider access to the new treatments, even in remote areas.
- What are the goals of introducing these new therapies to the Ugandan market?
- The new treatments are designed to manage symptoms and prevent long-term complications, reducing the burden on healthcare resources and improving patient outcomes. They aim to alleviate the pill burden and reduce costs for families.
- What is the expected impact of these new treatments on Uganda's healthcare system?
- The introduction of these therapies is expected to have a significant impact on Uganda's healthcare system, improving efficiency and resource allocation by reducing emergency care and hospitalizations.